The feasibility of IFN-γ and IL-10 as surrogate markers to evaluating the activity of drugs against mycobacterium tuberculosis / 中国药学杂志
Chinese Pharmaceutical Journal
;
(24): 759-763, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-859746
ABSTRACT
OBJECTIVE:
To study the probability of IFN-γ and IL-10 being surrogate markers for evaluating the anti-TB activity of drugs.METHODS:
75 BALB/c mice infected with H37Rv using a Glas-col inhalation exposure system, were randomized into 13 groups. After 2 months of therapy, the numbers of CFU in the lungs and the levels of IFN-γ and IL-10 in blood were determined. The relevance of IFN-γ, IL-10 concentrations, the ratio of IFN-γ/IL-10 and CFU were evaluated respectively.RESULTS:
(1) CFU enumeration the CFU of treatment groups except Lfx and PAS were significantly different from that of negative control group; the CFU of every treatment groups were significantly different from that of positive group. (2) Levels of IFN-γ the levels of IFN-γ in peripheral blood of treatment groups except Lfx and PAS were significantly different from that of negative control group; the IFN-γ of every treatment groups were significantly different from that of positive group. (3) IL-10 There were differences exiting neither between treatment groups and negative group nor between any two treatment groups. (4) HFNγ/IL-10 significantly differences were displayed between CLF, LZD+Pto, LZD+CLF, LZD+Am, HRZ and negative group respectively, while no significantly differences showed between any pair of treatment groups, (5) positive corrections were displayed between IFN-γ, IL-10, IFN-γ/IL-10 and CFU, certainty factor(r2) were 0.688, 0.237, 0.582.CONCLUSION:
The levels of IFN-γ may be used to evaluate the anti-TB activity of drugs and may not be the surrogate markers to predict the CFU in vivo.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Controlled clinical trial
/
Prognostic study
Language:
Chinese
Journal:
Chinese Pharmaceutical Journal
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS